Shares of Savara Inc. (NASDAQ:SVRA - Get Free Report) traded up 7.8% during trading on Thursday. The company traded as high as $5.07 and last traded at $5.0890. Approximately 1,247,725 shares changed hands during mid-day trading, a decline of 32% from the average session volume of 1,839,121 shares. The stock had previously closed at $4.72.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on SVRA shares. HC Wainwright began coverage on Savara in a research report on Thursday, November 12th. They set a "buy" rating and a $10.00 price target on the stock. Citigroup reiterated a "market outperform" rating on shares of Savara in a report on Wednesday, October 7th. Royal Bank Of Canada set a $10.00 price target on Savara in a report on Wednesday, October 7th. Wall Street Zen cut shares of Savara from a "hold" rating to a "sell" rating in a report on Sunday, October 4th. Finally, JPMorgan Chase & Co. started coverage on shares of Savara in a report on Wednesday, October 7th. They issued an "overweight" rating and a $12.00 price target on the stock. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $10.29.
Check Out Our Latest Research Report on SVRA
Savara Trading Up 5.7%
The company has a market capitalization of $1.10 billion, a PE ratio of -8.12 and a beta of 0.32. The company has a debt-to-equity ratio of 0.28, a current ratio of 8.55 and a quick ratio of 8.55. The company's fifty day moving average is $4.88 and its 200-day moving average is $5.32.
Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.01. On average, analysts anticipate that Savara Inc. will post -0.68 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the company. Sterling Capital Management LLC lifted its holdings in shares of Savara by 842.8% in the 3rd quarter. Sterling Capital Management LLC now owns 5,063 shares of the company's stock valued at $26,000 after buying an additional 4,526 shares during the period. Principal Financial Group Inc. purchased a new position in shares of Savara during the 1st quarter worth $57,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Savara in the third quarter valued at approximately $54,000. Sequoia Financial Advisors LLC acquired a new position in Savara in the second quarter valued at about $69,000. Finally, Quarry LP raised its holdings in shares of Savara by 6,524.4% in the 3rd quarter. Quarry LP now owns 11,924 shares of the company's stock valued at $62,000 after buying an additional 11,744 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.
Savara Company Profile
(
Get Free Report)
Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara's lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.